文献速递中药与中成药合理使用中医内科

中医药增强免疫检查点抑制剂抗肿瘤疗效的机制探讨

Traditional Chinese medicine enhances the effectiveness of immune checkpoint inhibitors in tumor treatment: A mechanism discussion.
PubMed 文献 · J Ethnopharmacol · 2024-10-18

本文为叙述性综述,检索PubMed及中国知网2014年5月至2024年5月文献,筛选出30种与免疫检查点抑制剂(ICIs)联用的中药,总结其增强ICIs疗效、减轻免疫相关不良事件(irAEs)的机制。多数研究为基础实验,临床证据有限,需更大样本高质量临床试验确认。

要点

  • 中医药及其活性成分可通过调控PD-1、PD-L1、CTLA-4、IDO1等免疫检查点增强ICIs疗效。
  • 中医药还可通过调节肠道菌群、改善肿瘤微环境等机制与ICIs协同抗肿瘤。
  • 中医药联合ICIs可减轻irAEs,但现有研究以基础实验为主,临床证据不足。

核心结论

  • 中医药联合ICIs可发挥更好的抗肿瘤作用,但需更大样本和高质量临床试验确认。
  • 许多中药及其成分在实验研究中显示可增敏ICIs,为后续研发ICIs增强剂提供丰富选择。

研究设计与样本

  • 叙述性综述,检索PubMed和中国知网数据库,检索期为2014年5月至2024年5月。
  • 最终获得30种与ICIs联用的中药用于探讨机制。

主要发现

  • 中医药可增强ICIs疗效并减少irAEs。
  • 中医药及其活性成分通过调控PD-1、PD-L1、CTLA-4、IDO1等免疫检查点、调节肠道菌群、改善肿瘤微环境等机制与ICIs协同。
  • 多数中医药联合ICIs的研究为基础实验。

关键数值与推荐

  • 检索关键词包括ICIs与中医药、PD-1与中医药、PD-L1与中医药、CTLA-4与中医药、IDO1与中医药、Tim-3与中医药、TIGIT与中医药、irAEs与中医药。
  • 纳入涉及中医药或其成分与ICIs联用并探讨机制的文章。
  • 在PD-1以外的免疫检查点分子部分,因联合应用研究较少,纳入涉及中医药调控免疫检查点分子的研究。

临床怎么用

  • 中医药联合ICIs可能增敏增效并减轻irAEs,但临床决策需谨慎,当前证据主要来自基础实验。
  • 可关注调控PD-1、PD-L1、CTLA-4、IDO1等通路的中药及其活性成分作为ICIs辅助治疗的潜力。

局限性

  • 多数研究为基础实验,临床证据有限。
  • 需更大样本和高质量临床试验确认中医药联合ICIs的疗效与安全性。
  • PD-1以外的免疫检查点分子与中医药联合应用的研究较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Immune checkpoint inhibitors (ICIs) have altered the landscape of tumor immunotherapy, offering novel therapeutic approaches alongside surgery, chemotherapy, and radiotherapy and significantly improving survival benefits. However, their clinical efficacy is limited in some patients, and their use may cause immune-related adverse events (irAEs). Integrating traditional Chinese medicine (TCM) with ICIs has demonstrated the potential to boost sensitization and reduce toxicity. Clinical trials and experimental explorations have confirmed that TCM and its active components synergistically enhance the effectiveness of ICIs. AIMS: This narrative review summarizes the TCM practices that enhance the clinical efficacy and reduce irAEs of ICIs. This paper also summarizes the mechanism of experimental studies on the synergies of Chinese herbal decoctions, Chinese herbal preparation, and Chinese herbal active ingredients. Most of the studies on TCM combined with ICIs are basic experiments. We discussed the mechanism of TCM enhanced ICIs to provide reference for the research and development of TCM adjuvant immunotherapy. METHODS: We conducted a literature search using PubMed and Chinese National Knowledge Infrastructure databases, with a focus on herbal decoction, Chinese medicine preparations, and active ingredients that boost the effectiveness of ICIs and reduce irAEs. The search keywords were "ICIs and traditional Chinese medicine", "PD-1 and traditional Chinese medicine", "PD-L1 and traditional Chinese medicine", "CTLA-4 and traditional Chinese medicine", "IDO1 and traditional Chinese medicine", "Tim-3 and traditional Chinese medicine", "TIGIT and traditional Chinese medicine", "irAEs and traditional Chinese medicine". The search period was from May 2014 to May 2024. Articles involving the use of TCM or its components in combination with ICIs and investigating the underlying mechanisms were screened. Finally, 30 Chinese medicines used in combination with ICIs were obtained to explore the mechanism. In the part of immune checkpoint molecules other than PD-1, there were few studies on the combined application of TCM, so studies involving the regulation of immune checkpoint molecules by TCM were included. RESULTS: TCM has been shown to boost the effectiveness of ICIs and reduce irAEs. Researchers indicate that TCM and its active components can work synergistically with ICIs by regulating immune checkpoints PD-1, PD-L1, CTLA-4, and IDO1, regulating intestinal flora, improving tumor microenvironment and more. CONCLUSIONS: Combining TCM with ICIs can play a better anti-tumor role, but larger samples and high-quality clinical trials are necessary to confirm this. Many Chinese medicines and their ingredients have been shown to sensitize ICIs in experimental studies, which provides a rich choice for the subsequent development of ICI enhancers.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Wang M, Yang F, Kong J, et al. Traditional Chinese medicine enhances the effectiveness of immune checkpoint inhibitors in tumor treatment: A mechanism discussion. J Ethnopharmacol. 2024. PMID: 39427737. doi:10.1016/j.jep.2024.118955

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。